Journal of Translational Medicine

Table 3 Univariate and multivariate Cox regression analysis for overall survival (OS)

From: Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients

Characteristics	Univariate analysis				Multivariate analysis
Characteristics	Median OS (months)	HR	95% CI	p	HR	95% CI	p
All patients	30.3
Age
< 55	22.4	1.72	0.88–3.37	0.113
≥ 55	23.4
Gender
Male	23.3	0.70	0.36–1.38	0.307
Female	20
Primary tumor location
Colon	22.4	0.78	0.39–1.58	0.497
Rectum	22.85
Primary tumor surgery
Yes	39.4	0.17	0.08–0.37	< 0.0001	0.37	0.12–1.11	0.075
No	11.6
Response (12 weeks) (RECIST)
Favorable	41.6	0.26	0.06–1.14	0.074	0.1	0.02–0.58	0.011*
Adverse	16.8
Response (24 weeks) (RECIST)
Favorable	48.6	0.51	0.22–1.20	0.123
Adverse	14.8
K-RAS status
Mutated	36.9	1.95	0.96–3.97	0.064	1.58	0.68–3.68	0.289
Wild-type	55.4
Metastasis surgery
Operated	68.4	0.35	0.15–0.81	0.014	0.39	0.12–1.24	0.111
Non-operated	31.1
Synchronous metastasis
Yes	32.1	15.89	2.04–123.35	0.008	18.33	1.52–221.18	0.022*
No	68.4
CEA Basal
High	39.4	1.96	0.84–4.57	0.121
Standard	55.4
Basal Ca 19.9
High	22.4	1.68	0.87–3.24	0.123
Standard	55.4
CTC1
Favorable	21.6	0.32	0.72–2.79	0.319
Adverse	23.5
CTC1 VEGFR
Yes	66.5	0.53	0.25–1.15	0.109
No	36.9
CTC2
Favorable	39	1.36	0.62–3.01	0.442
Adverse	55.4
CTC2 VEGFR
Yes	36.9	1.44	0.31–6.66	0.640
No	41.6
CTC3
Favorable	55.4	0.52	0.22–1.26	0.149	0.35	0.12–0.99	0.049*
Adverse	22.4
CTC3 VEGFR
Yes	22.4	1.04	0.23–4.81	0.958
No	30.9

*: Statistically significant
CTC: circulating tumor cell; OS: overall survival; HR: hazard risk; CI: confidence interval; VEGFR: vascular endothelial growth factor receptor positive; RECIST: Response Evaluation Criteria in Solid Tumors; p: p value

Back to article page

ISSN: 1479-5876

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com